Case Study 12.1 — Compounded Semaglutide: A Legal Exception, an Industry, and the Narrowing

What this case is. A real, public, still-unfolding episode in United States drug regulation. Chapter 6 opened it and refused a verdict. §12.4 told it end to end. This case study slows the same sequence down and asks you to watch the mechanism — how a narrow legal exception, entirely reasonable on its own terms, met an unprecedented demand signal and produced an industry nobody designed.

What this case is not. It is not an argument that compounding is illegitimate, that compounders behaved badly, or that people who used compounded product made a mistake. Those are conclusions this case study will not reach for you. It is also not current: the legal position has changed since the events described and will change again. Verify anything you intend to rely on.

Part 1 — The rule that was working fine

Compounding is old. Before industrial pharmaceutical manufacturing, all medicine was compounded; a pharmacist prepared what a prescriber ordered. The practice survives because manufacturing does not serve everyone: a child who needs a strength nobody makes, a patient allergic to a preservative present in every commercial formulation, someone who cannot swallow a tablet, a product discontinued because it was unprofitable while a small number of patients still depend on it.

Because compounded preparations are made for a patient rather than for a market, they are not reviewed before sale. Nobody at a regulatory agency examines the formulation, the process, or the evidence. That is a deliberate and defensible trade: reviewing every individually compounded preparation would end the practice, and the practice is useful.

The trade only works if compounding stays small and stays complementary. So US law contains a limitation that follows directly from the logic: you may not compound what is essentially a copy of a commercially available approved drug. If the approved product exists and can be obtained, an unreviewed version has no function except to undercut a reviewed one on price — and the price difference is largely the review.

Federal law recognizes two categories of compounder, formalized in a 2013 statute passed after a fungal meningitis outbreak traced to contaminated compounded injections killed dozens of people. 503A pharmacies compound patient-specific prescriptions under state board oversight. 503B outsourcing facilities register with FDA, may produce larger batches without patient-specific prescriptions, must comply with current good manufacturing practice, and are subject to federal inspection. Neither produces an FDA-approved product. The 2013 law exists because the alternative had already killed people, which is worth remembering whenever anyone describes compounding oversight as bureaucratic excess.

Part 2 — The exception, and why it is right

The prohibition on copying approved drugs has an exception, and it is the load-bearing element of this entire case.

When a drug is on the FDA shortage list, the prohibition lifts.

Consider why. A patient with a prescription they cannot fill is not choosing between a reviewed product and an unreviewed one. They are choosing between an unreviewed product and nothing. The approved product's advantages are real but unavailable. In that situation a compounded version — with all its uncertainties — is plainly better than untreated disease, and a rule that forbade it would be converting a supply failure into a treatment failure.

The exception is well designed for the situation it imagines: a modest shortage of a drug used by a bounded population, filled temporarily by compounders while manufacturing recovers.

It was not designed for what happened next.

Part 3 — The demand signal

Two things converged.

First, the evidence arrived. STEP 1 reported roughly −15% of baseline body weight at 68 weeks in adults with overweight or obesity without diabetes, against roughly −2.4% on placebo, with both arms receiving lifestyle intervention. STEP 2 reported roughly −10% in adults with type 2 diabetes. These are magnitudes no previous pharmacotherapy approached, and the news travelled far outside medicine.

Second, supply could not follow. As §12.3 established, the constraint was aseptic fill-finish capacity and injector-pen assembly — buildings, validation campaigns, and line-by-line regulatory approvals, not chemistry. Demand could triple in a year. Sterile filling capacity could not.

Semaglutide went onto the shortage list.

Part 4 — What formed in the gap

The exception opened, and what came through it was not a handful of pharmacies serving stranded patients. It was an industry.

Telehealth platforms, med spas, weight-loss clinics, and a large number of compounders — 503A and 503B both — built businesses around supplying compounded semaglutide. Marketing was aggressive, ran on social platforms, and frequently omitted the fact that the product was not FDA-approved. Price was the central message, quoted against the branded list price rather than against what an insured patient would actually pay. Access was frictionless in a way that regulated pharmacy is not: an online intake form, a prescriber who never met the patient, and delivery to the door.

Within a remarkably short period, a very large number of people in the United States were taking a semaglutide product no regulator had reviewed.

And the population using it was not the population the exception imagined. §12.4 separates three users: someone who genuinely could not obtain the branded drug; someone who could obtain it but could not afford it; someone who wanted it cosmetically and did not meet any approved criterion. The exception was written with only the first in mind. All three walked through it.

Part 5 — What regulators found

Three concerns, of three different kinds.

Salt forms. Some products contained semaglutide sodium or semaglutide acetate rather than semaglutide base. Regulators stated plainly that these are not the same substance as the semaglutide in approved products and that their safety and effectiveness had not been established. Part of the explanation is unglamorous: ingredient-sourcing rules constrain what a compounder may lawfully use, and for some suppliers a salt form was the version they could obtain. The path from "I want to supply semaglutide" to "I am supplying semaglutide sodium" runs through procurement, not pharmacology.

Dosing errors. Approved products are supplied in pre-filled pens with dose-setting mechanisms. Compounded product typically arrives as a vial and a syringe. Regulators and poison control centers reported adverse events consistent with dosing errors, including errors arising from confusion between units of measurement when converting between how a dose was expressed and the markings on a syringe. The pen is not packaging. It is an engineered defense against the commonest failure mode in self-administered medicine, and removing it reintroduces exactly what it was built to prevent.

Provenance. Concerns were raised about active ingredient sourced from facilities that were not registered, not inspected, and in some cases not identifiable. When the supplier of an API cannot be established, nothing downstream can be — not identity, not purity, not potency, however competent the pharmacy compounding it.

Part 6 — The narrowing

Capacity came online. The shortage eased. The regulator removed semaglutide from the shortage list.

And the exception closed with it — because the exception was never about price. It was about availability. Once the approved product could be obtained, the legal basis for compounding a copy of it disappeared, whatever a person's ability to pay.

What followed was messy and remains so. Compounding interests brought litigation challenging the delisting decision. Transition periods of differing lengths applied to different categories of compounder. Patients and prescribers were widely confused about what was still permitted. Businesses built entirely on the exception found their model declared to be ending. Questions persist about which "personalized" variations — different strengths, added ingredients, combination products — fall inside or outside the remaining permissions.

As of this writing (2026) the aftermath is unresolved. Consult the regulator's compounding pages directly rather than any summary, including this one.

Part 7 — What the case actually teaches

Not that anyone was a villain. The exception was well designed for what it imagined. The demand was driven by a genuinely effective drug. The shortage had a real physical cause. Compounders were operating, in most cases, inside the law as it stood. Patients were solving real problems.

The lesson is structural: a narrow permission written for a small case will be used at whatever scale the surrounding incentives permit. Nothing in the rule anticipated a drug that tens of millions of people wanted, at a price many could not pay, in a shortage caused by a constraint money could not quickly relieve. The rule did not fail. It was simply asked a question it had never been asked before, and it answered the only way it could.

The rating from §12.5, restated. The claim "compounded semaglutide is equivalent to the branded product" is ❌ as generally stated — because the category spans a registered 503B facility using genuine semaglutide base under inspected quality systems and material of unclear origin supplied as a salt form without the delivery device. What is conceded is not small: the legitimate end of that range produces the same active molecule, and during a genuine shortage it solved a real problem for real patients. The ❌ rates the claim, not the molecule and not the patient.

Discussion questions

1. The shortage exception turns on availability, not on affordability. State the strongest case for that design, then the strongest case against it. If you would extend the exception to cover affordability, describe the rule you would write and name the first way it would be exploited.

2. Regulators raised three concerns: salt forms, dosing errors, and provenance. Rank them by how much they should change a patient's decision, and justify the ranking. Does your ranking change if the supplier is a registered 503B facility rather than an unnamed online vendor — and if so, that tells you something about which concern is really doing the work.

3. The pen is a delivery device, not a molecule. Argue that its absence is a trivial difference. Then argue that it is the single most important difference. Which argument survives contact with the adverse-event reports described in Part 5?

4. Take the three users from §12.4 one at a time. For each, state (a) what they were choosing between, (b) what risk they accepted, and (c) what their choice cost other people. Then say whether you reach the same verdict for all three — and if you do, identify what you actually judged.

5. During the shortage, patients with type 2 diabetes lost access to a medication they had taken for years, because demand from the weight indication consumed the supply. Who, if anyone, should have had authority to allocate scarce supply between indications? Evaluate at least three candidate decision-makers and give a real objection to each.

6. This case describes a rule that did not fail, was not abused by most participants, and still produced an outcome nobody would have designed. Identify one other domain — inside or outside medicine — where a narrow, well-intentioned exception scaled beyond its purpose. What, if anything, prevented the same outcome there?